TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07429240: PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

Sponsor: Precision BioSciences, Inc. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,008,000

Rescue Site Savings

+$9,236,525

Unlock Full NCT07429240 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07429240 Rescue Dossier →